R/R MM: Insights Into Optimal Dosing for Bispecifics

Panelist discusses how bispecifics have had a major impact in relapsed/refractory multiple myeloma (R/R MM) because they provide a different way of attacking myeloma, allow oncologists an opportunity to care for patients who cannot have CAR T therapy, and allow oncologist to treat patients who have had an aggressive relapse. The panelist further discusses the importance of bispecifics dosing specifically to maintain a response with the drug but also to prevent the risk of patient infection.

EP: 1.R/R MM: Treating Patients with CNS Metastases Involvement

EP: 2.Optimal Dosing Strategies and Managing AEs

EP: 3.R/R MM: Bispecifics in R/R MM: Key Takeaways

Now Viewing

EP: 4.R/R MM: Insights Into Optimal Dosing for Bispecifics

EP: 5.Bispecifics in R/R MM: AE Management and Sequencing

EP: 6.Future Perspectives in R/R MM

EP: 7.R/R MM Treatment Landscape: Role of Bispecifics

EP: 8.Clinical Pearls Surrounding the Use of Bispecifics in R/R MM

Video content above is prompted by the following

• How have bispecifics impacted the treatment landscape for R/R MM?
• What has been your experience with using bispecifics in practice?
• How are you currently dosing bispecifics in practice?
• What insights can you share for fellow oncologists regarding dosing?

Recent Videos